The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. These agents have become fully integrated into current treatment practices for unresectable locally advanced or metastatic bladder cancer.
- What are the sizes of the
clinicallyand commercially relevant drug-treatable bladder cancer populations, and how willdrug-treatment rates change over time?
- How is bladder cancer currently treated, and what are the (dis
)advantages of existing drugs? What is the expected market impact of recent approvals?
- Which of the emerging therapies
seemmost promising, and what sales/uptake could they secure in the bladder cancer market?
- What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the ten-year forecast period?
Geographies: United States, EU5, Japan.
Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.
Emerging Therapies: Phase III/PR: 6 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products.
Disease Landscape & Forecast provides